Recently introduced in India, Lifitegrast is being hailed as a novel FDA approved drug in the treatment of keratoconjuctivitis sicca (a severe form of dry eye, where basal tear production is absent). The drug works by reducing the surface inflammation which occurs due to the lack of tears. It has also been known to be protective on the corneal surface and carries a much better safety profile when compared to immunosuppressive agents such as cyclosporine. Lifitegrast will soon be available at Darshan eye care and will offer a viable treatment solution for patients with severe forms of dry eye disease.